# Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

Study · id `cardio:ct-nct06984822` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06984822](<https://clinicaltrials.gov/study/NCT06984822>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06984822

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06984822. Non-randomized; no masking; primary purpose prevention. Start 2025-08-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06984822, source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)
- Started: 2025-08-01 (actual) (ClinicalTrials.gov record NCT06984822, source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06984822, source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06984822, source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT06984822, source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06984822-2025-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
- Acronym: BiomarkerOCT
- Condition: Diabetic Macular Edema
- Condition: Visual Impairment
- Condition: Diabetes Mellitus
- Condition: Hyperglycaemia (Diabetic)
- Condition: Oxidative Stress
- Condition: Vascular Endothelial Growth Factor
- Condition: VEGF
- Intervention (Drug): Anti-VEGF treatment
- Intervention (Device): Dexamethasone implant
- Intervention (Other): Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Lead sponsor: Vastra Gotaland Region
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Vastra Gotaland Region (`cardio:org-vastra-gotaland-region`)

## Provenance

Content hash: a63e3cd952556b365db4ae7b9997c9d47cde52bd27c0484b8c2e5052e6e74906
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
